Biologics comparability protocol approval could lessen manufacturing changes reporting -- CBER's Zoon.
BIOLOGICS "COMPARABILITY PROTOCOL" COULD LESSEN REPORTING REQUIREMENTS, under the final rule on changes to an approved application, Center for Biologics Evaluation & Research Director Kathryn Zoon told a Food & Drug Law Institute conference on July 23. The comparability protocol "will allow the manufacturer to reduce the level of risk by putting it in a lower category based on protocol defining how you are going to do the comparison study." Zoon said that "essentially a substantial risk item moves to a moderate risk, and likewise a moderate risk might move down to an annual report-type notification, depending on its comparability protocol."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth